WO2009069682A1 - 肝炎の治療剤又は予防剤 - Google Patents

肝炎の治療剤又は予防剤 Download PDF

Info

Publication number
WO2009069682A1
WO2009069682A1 PCT/JP2008/071508 JP2008071508W WO2009069682A1 WO 2009069682 A1 WO2009069682 A1 WO 2009069682A1 JP 2008071508 W JP2008071508 W JP 2008071508W WO 2009069682 A1 WO2009069682 A1 WO 2009069682A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleotides
length
hepatitis
agent
oligonucleotide
Prior art date
Application number
PCT/JP2008/071508
Other languages
English (en)
French (fr)
Inventor
Tomokatsu Iwamura
Akiko Soneda
Original Assignee
Toray Industries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries, Inc. filed Critical Toray Industries, Inc.
Priority to JP2009543838A priority Critical patent/JP5359883B2/ja
Publication of WO2009069682A1 publication Critical patent/WO2009069682A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

本発明は、インターフェロン（ＩＦＮ）誘導活性が増強され、かつ炎症性サイトカイン誘導活性が低減された新規な免疫刺激オリゴヌクレオチドと、インターフェロン－βとの併用による、肝炎の治療剤又は予防剤を提供することを目的とする。本発明は、式（１）：５’－（Ｇ）ＭＰＸＣＧＹＱ（Ｇ）Ｎ－３’[式（１）中、Ｃは、シトシン、Ｇは、グアニン、Ｘ及びＹは、それぞれ独立に、４塩基以上連続したグアニンを含まない０～１０ヌクレオチド長の塩基配列（但し、Ｘ＋Ｙの長さは、６～２０ヌクレオチド長である。）、ＸＣＧＹは、少なくとも８ヌクレオチド長のパリンドローム配列を含む８～２２ヌクレオチド長の塩基配列、Ｐ及びＱは、それぞれ独立に、グアニン以外の１ヌクレオチド、Ｍは、６～１０の整数、Ｎは、０～３の整数を表す。]で示され、全長が１６～３７ヌクレオチド長であるオリゴヌクレオチド（但し、配列表の配列番号５記載の塩基配列からなるものは除く。）と、インターフェロン－βと、を有効成分とする、肝炎の治療剤又は予防剤を提供する。
PCT/JP2008/071508 2007-11-28 2008-11-27 肝炎の治療剤又は予防剤 WO2009069682A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009543838A JP5359883B2 (ja) 2007-11-28 2008-11-27 肝炎の治療剤又は予防剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-307930 2007-11-28
JP2007307930 2007-11-28

Publications (1)

Publication Number Publication Date
WO2009069682A1 true WO2009069682A1 (ja) 2009-06-04

Family

ID=40678574

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/071508 WO2009069682A1 (ja) 2007-11-28 2008-11-27 肝炎の治療剤又は予防剤

Country Status (2)

Country Link
JP (1) JP5359883B2 (ja)
WO (1) WO2009069682A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11578331B2 (en) 2015-09-09 2023-02-14 Gilead Sciences, Inc. Combination comprising immunostimulatory oligonucleotides
US11583581B2 (en) 2015-09-21 2023-02-21 Gilead Sciences, Inc. Methods of treating a retroviral infection

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005083076A1 (ja) * 2004-02-27 2005-09-09 Emori & Co., Ltd. インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
JP2005532067A (ja) * 2002-07-03 2005-10-27 コーリー ファーマシューティカル グループ，インコーポレイテッド 刺激性免疫応答用の核酸組成物
JP2005533035A (ja) * 2002-06-03 2005-11-04 アプライド リサーチ システムズ アルス ホールディング ナムローゼ フエンノートシャップ インターフェロン−β皮下投与によるアジア人集団のＣ型肝炎治療
WO2006035939A1 (ja) * 2004-09-30 2006-04-06 Osaka University 免疫刺激オリゴヌクレオチドおよびその医薬用途
WO2006108358A1 (fr) * 2005-04-13 2006-10-19 Changchun Huapu Biotechnology Co., Ltd. UTILISATION ANTIVIRALE D’OLIGODESOXYNUCLEOTIDES ARTIFICIELS A UN SEUL BRIN CONTENANT UN CpG EN COMBINAISON AVEC LA RIBAVIRINE
JP2007528848A (ja) * 2003-07-09 2007-10-18 ヴァックスデザイン・コーポレーション ワクチン接種ノードを用いるプログラムされた免疫応答

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533035A (ja) * 2002-06-03 2005-11-04 アプライド リサーチ システムズ アルス ホールディング ナムローゼ フエンノートシャップ インターフェロン−β皮下投与によるアジア人集団のＣ型肝炎治療
JP2005532067A (ja) * 2002-07-03 2005-10-27 コーリー ファーマシューティカル グループ，インコーポレイテッド 刺激性免疫応答用の核酸組成物
JP2007528848A (ja) * 2003-07-09 2007-10-18 ヴァックスデザイン・コーポレーション ワクチン接種ノードを用いるプログラムされた免疫応答
WO2005083076A1 (ja) * 2004-02-27 2005-09-09 Emori & Co., Ltd. インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
WO2006035939A1 (ja) * 2004-09-30 2006-04-06 Osaka University 免疫刺激オリゴヌクレオチドおよびその医薬用途
WO2006108358A1 (fr) * 2005-04-13 2006-10-19 Changchun Huapu Biotechnology Co., Ltd. UTILISATION ANTIVIRALE D’OLIGODESOXYNUCLEOTIDES ARTIFICIELS A UN SEUL BRIN CONTENANT UN CpG EN COMBINAISON AVEC LA RIBAVIRINE

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAMSTRUP, S. ET AL.: "Response of porcine peripheral blood mononuclear cells to CpG- containing oligodeoxynucleotides", VET MICROBIOL, vol. 78, no. 4, 2001, pages 353 - 362 *
YAMAMOTO, S. ET AL.: "Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity", J IMMUNOL, vol. 148, no. 12, 1992, pages 4072 - 4076 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11578331B2 (en) 2015-09-09 2023-02-14 Gilead Sciences, Inc. Combination comprising immunostimulatory oligonucleotides
US11583581B2 (en) 2015-09-21 2023-02-21 Gilead Sciences, Inc. Methods of treating a retroviral infection

Also Published As

Publication number Publication date
JPWO2009069682A1 (ja) 2011-04-14
JP5359883B2 (ja) 2013-12-04

Similar Documents

Publication Publication Date Title
ATE416183T1 (de) Oligonukleotide mit alternierenden segmenten und deren verwendungen
WO2007112028A3 (en) 2'-fluoronucleoside phosphonates as antiviral agents
IL188362A0 (en) Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
WO2007020193A3 (en) Antiviral phosphoramidates of 4 ' -substituted pronucleotides
WO2006039488A3 (en) Hcv ns3-ns4a protease inhibition
PL366726A1 (en) 4'-substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus
EP2348112A3 (en) Stabilized immune modulatory RNA (SIMRA) compounds
WO2002069903A3 (en) Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
WO2001077091A3 (en) Ns5b hcv polymerase inhibitors
GB2431404A (en) Peptide
JP2008526876A5 (ja)
WO2007070598A8 (en) Nucleotide and oligonucleotide prodrugs
WO2004041201A3 (en) Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
WO2006032041A3 (en) Compositions and methods for inhibiting expression of anti-apoptotic genes
HK1104302A1 (en) Short interfering rna, short hairpin rna and coding vectors thereof, related compositions and use thereof used for inhibiting influenza virus infection
WO2008116860A3 (en) Dsrna compositions and methods for treating hpv infections
TR200302313T4 (tr) Antivirütik pirimidin nükleosid analogları
WO2007127919A3 (en) Compositions and methods for inhibiting expression of a gene from the jc virus
AU3295700A (en) Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same
WO2003101394A3 (en) Defensins: use as antiviral agents
EP1892293A4 (en) TRANSCRIPTION FACTOR DECOY
MXPA04004621A (es) Nucleotidos, preparaciones de los mismos y su utilizacion como inhibidores de polimerasas virales de arn.
HK1159988A1 (en) Compositions and methods for inhibiting expression of factor v leiden mutant gene
WO2009069682A1 (ja) 肝炎の治療剤又は予防剤
WO2009069447A1 (ja) インフルエンザワクチン用のアジュバント及びインフルエンザワクチン

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08854921

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009543838

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08854921

Country of ref document: EP

Kind code of ref document: A1